Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25132942 | 0.91 | CHRM1 (0.33) | CHRM1 | |
| SCHEMBL14486765 | 0.80 | DPP4 (0.40) | DPP4PREPFAP | |
| SCHEMBL17035919 | 0.76 | CHRM1 (0.35) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL25132318 | 0.76 | CA12 (0.31) | — | |
| SCHEMBL21100046 | 0.76 | ALDH1A1 (0.35) | ALDH1A1TDP1 | |
| SCHEMBL888859 | 0.76 | — | — | |
| SCHEMBL23879808 | 0.75 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL25132355 | 0.75 | — | — | |
| SCHEMBL14511683 | 0.75 | NOS3 (0.42) | — | |
| SCHEMBL14410299 | 0.75 | RIPK1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | HYSLINK THERAPEUTICS (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | SI, MET, MTX1 | CHRM1 1529/4885DPP4 631/4885PREP 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.